Dr. E. Prashanthi Reddy
MBBS · DGO · Diploma in ART — Kiel University, Germany
Founder & Medical Director — Mother Hospitals & IVF Center, Boduppal
TGMC Registration: 50624 · 19+ Years of Clinical Experience · 5000+ IVF Cycles
Gestational diabetes diagnosed and managed with personalised diet plans, glucose monitoring, insulin therapy when needed, and close fetal surveillance. Dr. E. Prashanthi Reddy, Boduppal.
Gestational diabetes mellitus (GDM) is glucose intolerance that is first detected during pregnancy. India has one of the highest rates of GDM in the world.
During pregnancy, the placenta produces hormones — including human placental lactogen, oestrogen, and cortisol — that cause progressive insulin resistance. In most women, the pancreas compensates by producing more insulin. In women who develop GDM, the pancreatic response is insufficient — blood glucose rises above normal levels. This is not a failure of willpower or diet — it is a physiological response to pregnancy that some women are predisposed to.
GDM affects 10–15% of pregnancies in India — significantly higher than the global average of 6–9%. Indian women have a genetic predisposition to insulin resistance and central obesity. Women with PCOS, a family history of Type 2 diabetes, previous GDM, or high BMI are at particularly elevated risk. Early screening and proactive management are essential in the Indian obstetric context.
In most cases, GDM resolves completely after delivery, as the placental hormones causing insulin resistance are removed. However, GDM is a marker of underlying insulin resistance — women who have had GDM carry approximately a 50% lifetime risk of developing Type 2 diabetes. Annual HbA1c testing and a healthy lifestyle after pregnancy are strongly recommended to delay or prevent this progression.
Home blood glucose monitoring (glucometer) is central to GDM management — Dr. Prashanthi advises on frequency and timing of testing at diagnosis.
The 75g Oral Glucose Tolerance Test (OGTT) is the standard diagnostic test for GDM in India and internationally.
All pregnant women are offered an OGTT at 24–28 weeks. You fast for at least 8 hours overnight, then drink a 75g glucose solution at the laboratory. Blood glucose is measured at three points: fasting (0 hours), 1 hour, and 2 hours after the glucose drink. The test takes approximately 2 hours in total. GDM is diagnosed if any single value is at or above the diagnostic threshold:
Women at high risk of GDM are screened at the first antenatal booking visit (regardless of gestational age) with a fasting glucose or HbA1c, or a full OGTT. If negative at booking, they are rescreened again at 24–28 weeks. High-risk criteria include:
Understanding your risk allows earlier screening and intervention — reducing the impact of GDM on you and your baby.
BMI above 30 at the start of pregnancy significantly increases insulin resistance. Excess adipose tissue secretes inflammatory cytokines that impair insulin signalling. Weight management before pregnancy is one of the most effective ways to reduce GDM risk.
A first-degree relative (parent or sibling) with Type 2 diabetes doubles the risk of GDM. Indian women have a genetic predisposition to beta-cell insufficiency and insulin resistance that is amplified during pregnancy.
Women with PCOS have pre-existing insulin resistance and androgen excess. This makes them significantly more likely to develop GDM and should be screened earlier in pregnancy. Good pre-pregnancy PCOS management reduces (but does not eliminate) GDM risk.
Women who had GDM in a previous pregnancy have a 30–70% risk of recurrence in subsequent pregnancies. Early screening from booking and proactive dietary measures from conception are recommended in this group.
A previous baby weighing more than 4 kg (macrosomia) suggests undiagnosed or borderline GDM in a previous pregnancy, or constitutional large baby tendency. Either way, earlier GDM screening is warranted.
Insulin sensitivity declines with age. Women conceiving over age 35 have a higher baseline risk of GDM. Combined with other risk factors (PCOS, BMI, family history), the risk may be substantially elevated.
For approximately 70% of women with GDM, diet modification alone is sufficient to achieve glucose targets. This is always the first and most important treatment.
A gentle 15–20 minute walk after each main meal significantly reduces post-meal blood glucose levels — often more effectively than medication in mild GDM. This is simple, safe in pregnancy, and strongly recommended. Swimming, prenatal yoga, and stationary cycling are also excellent. Avoid high-impact or high-intensity exercise without medical clearance in pregnancy.
Women with GDM check their blood glucose at home using a glucometer — typically fasting on waking, and 1–2 hours after each main meal (4–7 readings per day). This allows real-time assessment of whether dietary choices are working. Dr. Prashanthi reviews glucose diary results at each antenatal visit and adjusts the management plan accordingly.
Approximately 30% of women with GDM require medication in addition to diet. Fear of insulin should never delay treatment — uncontrolled GDM is far more harmful.
Metformin (an oral tablet) reduces hepatic glucose production and improves insulin sensitivity. It is used as the first medication in women with mild GDM who do not achieve targets with diet alone, and who are not happy to start insulin. Metformin is safe in pregnancy — it has been used in obstetrics for over 20 years and is well-studied. A small amount crosses the placenta but no harm to the baby has been demonstrated.
Insulin does not cross the placenta and has absolutely no direct effect on the baby. It is one of the safest treatments used in pregnancy. Insulin is recommended when: diet alone does not achieve glucose targets, metformin is insufficient, fasting glucose is significantly elevated (where metformin is less effective), or when rapid glucose control is needed for fetal wellbeing.
Dr. Prashanthi provides full training and ongoing support for self-administration of insulin — including pen device use, injection technique, dose adjustment, and hypoglycaemia awareness. Most women find that insulin injections are far less frightening in practice than they feared.
GDM pregnancies require closer fetal surveillance than uncomplicated pregnancies — to detect macrosomia, growth changes, and wellbeing concerns early.
Serial growth scans assess estimated fetal weight, abdominal circumference (the most sensitive indicator of macrosomia — a large abdomen reflects glucose-driven fat deposition), and amniotic fluid volume. If the baby's growth is above the 90th centile for gestational age, delivery planning is brought forward and glucose control is reviewed urgently.
Cardiotocography (CTG) monitors the fetal heart rate for 20–30 minutes to assess fetal wellbeing. A reactive trace (accelerations with fetal movement) is reassuring. In women with poorly controlled GDM or macrosomia, NST may be performed more frequently and from an earlier gestation (32–34 weeks).
If fetal growth is abnormal (either macrosomic or growth-restricted), Doppler measurement of blood flow in the umbilical artery, middle cerebral artery, and ductus venosus provides additional information about placental function and fetal circulatory adaptation. Abnormal Doppler findings may accelerate delivery planning.
Most women with well-controlled GDM can safely continue to 38–40 weeks. If glucose control is poor, if the baby is macrosomic (estimated weight above 4 kg), or if other complications develop, delivery is planned at 37–38 weeks — by induction of labour or elective C-section depending on clinical circumstances and patient preference. Dr. Prashanthi discusses the planned delivery approach clearly from 36 weeks.
The following risks apply to poorly controlled GDM — not to well-managed GDM. Good management eliminates or dramatically reduces all of them.
Key message: All these risks are avoidable or dramatically reduced with good GDM management. You are not powerless — and Dr. Prashanthi will guide you every step of the way.
GDM usually resolves after delivery — but the journey does not end there.
All women who had GDM should have a blood glucose test (OGTT or fasting glucose) at the 6-week postnatal check. This confirms that GDM has resolved. Approximately 5–10% of women will have persistent glucose abnormality (impaired fasting glucose, impaired glucose tolerance, or frank Type 2 diabetes) at this point — and require ongoing management.
Even if the 6-week test is normal, annual HbA1c testing is strongly recommended long-term. Women who maintain a healthy weight, follow a low-GI diet, and exercise regularly can reduce their 50% lifetime diabetes risk by more than 50%. Dr. Prashanthi discusses this at every postpartum visit.
MBBS · DGO · Diploma in ART — Kiel University, Germany
Founder & Medical Director — Mother Hospitals & IVF Center, Boduppal
TGMC Registration: 50624 · 19+ Years of Clinical Experience · 5000+ IVF Cycles
Common questions about gestational diabetes, the OGTT, diet, insulin, and delivery.
Gestational diabetes (GDM) is a type of glucose intolerance that develops during pregnancy in women who did not have diabetes before. It occurs because pregnancy hormones (produced by the placenta) cause insulin resistance — the body cannot use insulin effectively. In most cases, GDM resolves completely after delivery. However, women who have had GDM have approximately a 50% lifetime risk of developing Type 2 diabetes, so lifestyle vigilance and annual glucose monitoring after pregnancy are strongly recommended.
The Oral Glucose Tolerance Test (OGTT) is the standard test for gestational diabetes. It is routinely performed between 24 and 28 weeks of pregnancy (earlier if you are high-risk). You fast overnight for at least 8 hours, then drink a 75g glucose solution at the lab. Blood glucose is measured at fasting, 1 hour, and 2 hours after the glucose drink. The test takes approximately 2 hours. GDM is diagnosed if any ONE value is at or above the threshold: fasting ≥92 mg/dL, 1-hour ≥180 mg/dL, 2-hour ≥153 mg/dL.
Yes, for approximately 70% of women. The cornerstone of GDM management is a low glycaemic index (low-GI) diet — reducing refined carbohydrates, avoiding sugary drinks, eating regular small meals, and including protein at each meal. Short walks after meals significantly improve post-meal glucose levels. Blood glucose is monitored at home (fasting and 1–2 hours after each main meal) to assess whether dietary changes are achieving target glucose levels. If targets are consistently not met despite good dietary compliance, medication (metformin or insulin) is added.
Yes. Insulin does not cross the placenta and has no direct effect on the baby. It is one of the safest medications used in pregnancy. Fear of insulin is common but should not lead to delayed treatment — poorly controlled blood glucose is far more harmful to the baby than insulin therapy. Insulin injections during pregnancy use fine, short needles and cause minimal discomfort. Dr. Prashanthi provides full training and support for self-administration of insulin, including dose adjustment guidance.
Not necessarily — and not if GDM is well managed. When blood glucose is kept within target ranges throughout pregnancy, the baby's growth is usually normal. However, if GDM is poorly controlled, excess glucose crosses the placenta, the baby's pancreas produces more insulin in response, and this causes accelerated growth (macrosomia — birth weight above 4 kg). This is why close monitoring with growth scans and good glucose control are so important. A macrosomic baby increases the risk of difficult delivery and C-section.
Uncontrolled GDM carries risks including: macrosomia (large baby), preterm birth, neonatal hypoglycaemia (low blood sugar in the baby after birth, requiring monitoring in the neonatal unit), respiratory distress syndrome, and a higher risk of the child developing obesity and diabetes in later life. However, ALL of these risks can be dramatically reduced or eliminated with good GDM management. Well-controlled GDM pregnancies have outcomes equivalent to non-diabetic pregnancies. This is why early diagnosis and proactive management matter so much.
Not automatically. Many women with well-controlled GDM deliver vaginally at term. A C-section may be recommended if: the baby is estimated to be very large (macrosomia, estimated weight above 4 kg), if there is concern about shoulder dystocia during vaginal delivery, if GDM is poorly controlled and early delivery is planned, or for other obstetric indications unrelated to GDM. The mode of delivery is discussed with Dr. Prashanthi from 36 weeks based on glucose control, growth scans, and individual circumstances.
In the vast majority of cases, yes — blood glucose returns to normal shortly after the placenta is delivered, as the placental hormones causing insulin resistance are removed. A confirmatory blood glucose test (OGTT or HbA1c) is performed at the 6-week postnatal check to confirm resolution. However, women who have had GDM have approximately a 50% lifetime risk of Type 2 diabetes. Annual HbA1c testing, maintaining a healthy weight, regular exercise, and a low-GI diet significantly reduce this long-term risk.
Explore other specialist services at Mother Hospitals & IVF Center.
Gestational diabetes, managed well, does not have to compromise your pregnancy or your baby's health. Dr. E. Prashanthi Reddy provides personalised GDM management — from diagnosis to delivery and beyond.
Dr. E. Prashanthi Reddy · TGMC Reg: 50624